Discovery of a common mechanistic defect and potential therapies …
2024年10月8日 · A new study 1 described the underlying defect responsible for development of age-related macular degeneration (AMD) and related macular dystrophies (MDs), such as Sorsby’s fundus dystrophy, Doyne honeycomb macular dystrophy, and autosomal dominant radial drusen.. The investigators, led by Sonal Dalvi, PhD, showed that reduced activity of matrix metalloproteinase 2 (MMPs) secreted from the ...
jCyte, Inc. announces pivotal trial of jCell for RP to start in second ...
2024年2月24日 · jCyte, Inc. announced in a press release the positive pre-phase 3 FDA type B meeting that took place on January 16. The pivotal trial of jCell to treat retinitis pigmentosa (RP) is scheduled to start enrollment during the second half of 2024.
Study suggests visual system affected in patients with mild …
2024年12月8日 · The results of a new study 1 suggested that the visual system is affected in patients with mild traumatic brain injury (TBI), even in patients who do not report visual disturbances, according to Marselle Rasdall, MD, from Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville. The research team …
AAO 2024: Deuterated vitamin A preserves vision in Stargardt …
2024年10月20日 · Christine N. Kay, MD, discussed her presentation, "Deuterated vitamin A preserves vision in Stargardt’s disease (TEASE study)" which was given at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.
More than 300 patients randomized in the SOL-1 Phase 3 trial for …
2024年12月3日 · More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The trial is expected to close randomization in early December 2024.
Phototherapeutic keratectomy-assisted, customized, epi-on …
2024年10月20日 · Farhad Hafezi, FARVO, MD, PhD, and colleagues reported on the results achieved with phototherapeutic keratectomy (PTK)-assisted, customized, epi-on corneal crosslinking (CXL) (PACE), from the Swiss-based Elza Institute) that is a new take on CXL, in that it is not intended to just stable corneal tissue but to provide profoundly improved vision in patients with keratoconus (KCN) without ...
FDA authorizes marketing of Valeda Light Delivery System for …
2024年11月12日 · The US Food & Drug Administration (FDA) has authorized marketing of Valeda Light Delivery System for treatment of patients with dry age-related macular degeneration (AMD).
AAO 2024: An update from Neurotech on its MacTel treatment …
2024年10月18日 · Thomas Aaberg, Jr, MD, Neurotech's Chief Medical Officer, shared some insights on the company's recent presentation as well as their upcoming presentations at the annual American Academy of Ophthalmology meeting being held in Chicago, Illinois.
First patient dosed in phase I/IIa clinical trial of ABI-110
2024年11月23日 · The first patient has been successfully dosed in the Phase I/IIa clinical trial of ABI-110, Avirmax Biopharma 's first gene therapy drug for the treatment of wet age-related macular degeneration (AMD) including polypoidal choroidal vasculopathy (PCV).
First patients enrolled in the CLARITY phase 3 study
2024年9月28日 · Priovant Therapeutics has enrolled the first patients in the CLARITY Phase 3 study evaluating brepocitinib in non-anterior non-infectious uveitis (NIU).